Pharvaris N.V. PHVS · SEC Filings

website

148

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercializa...

Price34.47

Market Cap2.41 B

Float33.6 M

CountryCH

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

Prospectus

TYPE

HEADLINE

FILED AT

Registrations

TYPE

HEADLINE

FILED AT

POSASR

Form POSASR - Post-effective Amendment to an automatic shelf registration statement

Sep 23, 2025

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Jul 22, 2025

F-3ASR

April 2024 SHELF + ATM

Apr 12, 2024

F-3ASR

SHARE RESALE REGISTRATION

Mar 6, 2024

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Dec 6, 2023

F-3

SHARE RESALE REGISTRATION | Shares amount: 6,951,340

Aug 7, 2023

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

Lu Peng (Reporting)

Oct 13, 2026

Monges Viviane (Reporting)

Sep 25, 2026

Lu Peng (Reporting)

Sep 24, 2026

Schikan Johannes Gerardus Christiaan Petrus (Reporting)

Sep 24, 2026

144

Form 144 - Report of proposed sale of securities

Sep 23, 2026

Nassif David W. (Reporting)

Sep 23, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Aug 11, 2025

CORRESP

Form CORRESP - Correspondence

Aug 6, 2025

LETTER

Form UPLOAD - SEC-generated letter

Jul 24, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 17, 2023

CORRESP

Form CORRESP - Correspondence

Aug 15, 2023

LETTER

Form UPLOAD - SEC-generated letter

Aug 14, 2023